Vedere Bio II, gene therapy biotech born out of Novartis buyout, closes down
When Novartis swooped in to buy Vedere Bio and its preclinical gene therapy for $150 million upfront in 2020, Vedere CEO Cyrus Mozayeni — who helped form the startup just the year before in Atlas Venture’s incubator — took the team and the rest of the earlier-stage programs to a new company.
They called it Vedere Bio II, and unveiled a $77 million Series A in 2021. But they couldn’t repeat the success. Two years after that launch, Vedere Bio II is shutting down.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
